These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24843712)

  • 21. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.
    White JL; Buchanan P; Li J; Frederich R
    BMC Endocr Disord; 2014 Feb; 14():17. PubMed ID: 24565221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study.
    Ishihara H; Yamaguchi S; Nakao I; Asahina S; Sakatani T
    Diabetol Int; 2019 Jan; 10(1):37-50. PubMed ID: 30800562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teneligliptin for the treatment of type 2 diabetes.
    Goda M; Kadowaki T
    Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
    Kadowaki T; Marubayashi F; Yokota S; Katoh M; Iijima H
    Expert Opin Pharmacother; 2015 May; 16(7):971-81. PubMed ID: 25861982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teneligliptin in management of type 2 diabetes mellitus.
    Sharma SK; Panneerselvam A; Singh KP; Parmar G; Gadge P; Swami OC
    Diabetes Metab Syndr Obes; 2016; 9():251-60. PubMed ID: 27574456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
    Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
    Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Teneligliptin on HbA1c levels, Continuous Glucose Monitoring-Derived Time in Range and Glycemic Variability in Elderly Patients with T2DM (TEDDY Study).
    Bae JC; Kwak SH; Kim HJ; Kim SY; Hwang YC; Suh S; Hyun BJ; Cha JE; Won JC; Kim JH
    Diabetes Metab J; 2022 Jan; 46(1):81-92. PubMed ID: 34130378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Hiroi S; Hirayama M; Kaku K
    J Diabetes Investig; 2012 Dec; 3(6):517-25. PubMed ID: 24843617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial.
    Yokoh H; Kobayashi K; Sato Y; Takemoto M; Uchida D; Kanatsuka A; Kuribayashi N; Terano T; Hashimoto N; Sakurai K; Hanaoka H; Ishikawa K; Onishi S; Yokote K
    J Diabetes Investig; 2015 Mar; 6(2):182-91. PubMed ID: 25802726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.
    Nino A; Okuda I; Wilson TH; Yue L; Nakajima H; Tsuboi M; Carr MC; Seino Y
    J Diabetes Investig; 2017 Sep; 9(3):558-66. PubMed ID: 28921915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QT/QTc safety and efficacy evaluation of teneligliptin in Indian type 2 diabetes mellitus patients: the "thorough QT/QTc" study (Q-SET study).
    Erande S; Sarwardekar S; Desai B
    Diabetes Metab Syndr Obes; 2019; 12():961-967. PubMed ID: 31417296
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
    Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
    Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
    Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks.
    Kadowaki T; Tajima N; Odawara M; Nishii M; Taniguchi T; Ferreira JC
    J Diabetes Investig; 2013 Mar; 4(2):174-81. PubMed ID: 24843649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.
    Hirose T; Suzuki M; Tsumiyama I
    Diabetes Ther; 2015 Dec; 6(4):559-571. PubMed ID: 26620049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
    Seino Y; Inagaki N; Haneda M; Kaku K; Sasaki T; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
    J Diabetes Investig; 2015 Jul; 6(4):443-53. PubMed ID: 26221523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.